EGFR and colorectal carcinoma: Acknowledging the high number of factors capable of signaling through the EGFR/HER‐family of receptors, additional studies are required to comprehensively investigate the levels of all potential ligands as potential predictive biomarkers for EGFR‐targeting therapies in CRC.